via NIH
American and European researchers publish study in Nature Medicine reporting a new, single treatment option for cystic fibrosis patients
Researchers from the George Washington University (GW), the University of Perugia, and the University of Rome have discovered a potential new drug to treat and stop the progression of cystic fibrosis. Thymosin ?1 (T?1) is a novel therapeutic single molecule-based therapy that not only corrects genetic and tissue defects, but also significantly reduces inflammation seen in cystic fibrosis patients.
“Right now there are multiple treatments for cystic fibrosis, and while these have improved life expectancy dramatically, there is still only a lifespan of about 40 years for patients. No one treatment can stand alone,” said Allan L. Goldstein, Ph.D., co-author of the paper and Professor Emeritus in Residence of Biochemistry and Molecular Medicine at the GW School of Medicine and Health Sciences. “We developed a single treatment that can potentially correct the genetic defect that causes cystic fibrosis and decrease the inflammation that happens as a result.”
Cystic fibrosis is a genetic disease that causes persistent lung infections and limits the ability to breathe over time, and it affects approximately 70,000 worldwide and 30,000 in the U.S. alone. Cystic fibrosis is the result of mutations in the gene encoding the protein called the cystic fibrosis transmembrane conductance regulator (CFTR), which is important to maintain chloride-channel activity affecting the salt and water balance in the lungs. This mutation results in a misfolded CFTR protein, and its premature degradation leads to impaired chloride permeability and persistent lung inflammation.
Goldstein and co-authors Luigina Romani, Ph.D., M.D., at the University of Perugia and Enrico Garaci, M.D., at the University of Rome “San Raffaele,” both in Italy, published their results in Nature Medicine. They report that T?1, a synthetic version of a naturally occurring peptide first isolated from the thymus, corrects the multiple tissue defects found in the lungs and small intestines in a mouse model of cystic fibrosis, as well as the defects in the CFTR seen in cells isolated from cystic fibrosis patients. T?1 not only significantly reduces the inflammation seen in cystic fibrosis, but also increases CFTR maturation, stability, and activity. Due to this two-pronged action, T?1 offers a strong potential to be a single-molecule therapeutic agent to treat and stop the progression of cystic fibrosis.
Goldstein and colleagues first isolated and characterized T?1 as a biological response modifier with potent immune therapeutic activity in 1979. This research was done in large part at GW. Although the peptide is produced in small amounts in several peripheral lymphoid and non-lymphoid tissues, the highest concentrations of T?1 are found in the thymus. T?1, whose commercial name is Zadaxin, has been approved for clinical use for over 15 years in 35 countries in the treatment of patients with viral infections, immunodeficiency diseases, malignancies, and HIV/AIDS. Though not currently available in the U.S., it has an excellent safety profile and does not induce the side effects and toxicities commonly associated with most immunomodulatory agents.
Learn more: Research Uncovers Potential New Treatment to Treat and Stop Progression of Cystic Fibrosis
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- NHS spent £100million on deal with a US pharmaceutical firm for the wrong cystic fibrosis drugon November 30, 2019 at 6:14 pm
The Government has been accused of making an astonishing mistake by signing an estimated £100 million deal with a US pharmaceutical firm for an obsolete cystic fibrosis drug. Following an often bitter ...
- From lemonade to necklaces, young girl raises $100K for Cystic Fibrosis Canadaon November 29, 2019 at 2:22 pm
WATCH: An 11-year-old girl with cystic fibrosis (CF) has partnered with a Saskatoon jewelry shop to raise money for CF Canada. Saskatoon’s Elizabeth Lyn Jewelry partnered with eleven-year-old Cassidy ...
- Woman with cystic fibrosis left fighting for every breath as she waits for vital drugson November 28, 2019 at 8:16 pm
Nicole Adams, 28, coughs up 'thick green mucus' as a result of her cystic fibrosis. She is currently in Belfast Royal Victoria Hospital and only has 20% lung capacity ...
- Global Cystic Fibrosis Drugs Market by Drug Class, Route of Application & Region - Forecast to 2025on November 28, 2019 at 4:01 pm
DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Cystic Fibrosis Drugs Market By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements, and Others), By Route of Application ...
- Deer Lakes turkey trot raises money for cystic fibrosis researchon November 28, 2019 at 2:28 pm
They were also running for a good cause, and were among more than 100 people who took part in the run that raised money for the Cystic Fibrosis Foundation in honor of three girls in the community ...
- New Cystic Fibrosis drugs could take monthson November 27, 2019 at 9:01 am
The parents of Sebe and Ruby say they're devastated with the news Credit: ITV News Central The parents of two children who have Cystic Fibrosis say they're disappointed they won't have access to the ...
- Nanomolar-potency ‘co-potentiator’ therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutantson November 27, 2019 at 2:14 am
Available CFTR modulators provide no therapeutic benefit for cystic fibrosis (CF) caused by many loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride ...
- Survey Finds People with Cystic Fibrosis Using a CFTR Modulator Have Positive View of Treatment Plans, HCP Relationships, Futureon November 26, 2019 at 4:13 pm
Patients who have never used a modulator are more likely to say CF negatively impacts their overall quality of life PHILADELPHIA, Nov. 26, 2019 /PRNewswire/ -- A new survey from Health Union, Cystic ...
- New breakthrough medication offers hope for those with cystic fibrosison November 26, 2019 at 4:43 am
A new breakthrough therapy called Trikafta is being called a miracle for people with cystic fibrosis.Kathy Walsh has more from Denver, Colorado. A new breakthrough therapy called Trikafta is being ...
via Bing News